The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Tuberculosis chemotherapy: current drug delivery approaches
Open accessAbstract
Tuberculosis is a leading killer of young adults worldwide and the global scourge of multi-drug resistant tuberculosis is reaching epidemic proportions. It is endemic in most developing countries and resurgent in developed and developing countries with high rates of human immunodeficiency virus infection. This article reviews the current situation in terms of drug delivery approaches for tuberculosis chemotherapy. A number of novel implant-, microparticulate-, and various other carrier-based drug delivery systems incorporating the principal anti-tuberculosis agents have been fabricated that either target the site of tuberculosis infection or reduce the dosing frequency with the aim of improving patient outcomes. These developments in drug delivery represent attractive options with significant merit, however, there is a requisite to manufacture an oral system, which directly addresses issues of unacceptable rifampicin bioavailability in fixed-dose combinations. This is fostered by the need to deliver medications to patients more efficiently and with fewer side effects, especially in developing countries. The fabrication of a polymeric once-daily oral multiparticulate fixed-dose combination of the principal anti-tuberculosis drugs, which attains segregated delivery of rifampicin and isoniazid for improved rifampicin bioavailability, could be a step in the right direction in addressing issues of treatment failure due to patient non-compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahsan, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00549-1 · Cited by 570
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314
Cited by
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Sosnik, A., Carcaboso, Á. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.023 · Cited by 264
Pulmonary drug delivery systems for tuberculosis treatment
Pham, D.-D., Fattal, E., & Tsapis, N. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.12.009 · Cited by 185
The formulation of nanomedicines for treating tuberculosis
Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123
Alginate-based sustained release drug delivery systems for tuberculosis
Ahmad, Z., & Khuller, G. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802600662 · Cited by 63
Metadata
- Authors
- du Toit, L. C., Pillay, V., & Danckwerts, M. P.
- Venue
- Respiratory Research
- Published
- 2006-09-19
- Volume
- 7
- Issue
- 1
- Pages
- 118-118
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- OpenAlex
- W1519175806
- Cited by
- 212
- References
- 3
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tuberculosis chemotherapy: current drug delivery approaches. https://app.cochat.ai/papers/10.1186/1465-9921-7-118
- The paper
- du Toit, L. C., Pillay, V., & Danckwerts, M. P. (2006). Tuberculosis chemotherapy: current drug delivery approaches. Respiratory Research. https://doi.org/10.1186/1465-9921-7-118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.